

Vaccine Planning Work Group

In order to keep an accurate roll call, we ask that everyone joining this meeting rename themselves to include the following information:

- First Name
- Last Name
- Organization


Please type all questions into the chat box.

Presentations slides will be posted on the Maine Immunization Program website at:
<https://www.maine.gov/dhhs/mecdc/infectious-disease/immunization/covid-19-providers/communications.shtml>

We appreciate the time and effort taken by everyone joining to help the Maine CDC with COVID-19 vaccine planning.

Vaccine Planning Work Group

Tonya Philbrick
Maine Immunization Program
February 4, 2021



Disclaimer

All information in this presentation is subject to change.
Information shared in these slides are assumptions
as of 2/3/2021.

Agenda

- General Updates
- Vaccine Deliveries
- Ancillary Supplies
- Retail Pharmacy Next Phase
- VAERS

General Updates

2/2/2021

- 32 millions doses administered across the Nation
- 7.8 % of population
- States to see a 5% increase in vaccine allotments
- Additional Public Health Work Force
- Announcement of the Retail Pharmacy Soft Launch

Maine Doses administered 2/4/2021

- 167,111 total doses administered
- 123,683 first doses
- 43,428 final doses
- 3.23% of population that have received their final doses

Maine's Allotment Week #9 distribution

- 8,775 doses of Moderna
- 12,700 doses of Pfizer

Vaccine Deliveries

- Be prepared for delays during inclement weather.
- Ensure you have a plan to accept vaccine shipments.
- If other non-clinical staff sign for the shipment ensure protocols are in place for appropriate cold chain management.
- If shipments are delayed ensure once received the monitor reads within appropriate temperature.
- Be proactive.

Ancillary Supplies

Challenges with some ancillary supplies

- Over 49 million doses of the COVID-19 vaccine have been shipped thus far and with it, enough ancillary kits to support administration.
- It is understandable that with this volume of supplies, there may be an occasional defective item.
- If supplies arrive damaged, then the site should immediately contact McKesson Customer Services to report the damaged product.
- If during the course of administering a vaccine the item does not work as intended, then the event and the defective supply should be reported to the [Vaccine Adverse Event Reporting System \(VAERS\) \(hhs.gov\)](https://www.hhs.gov/vaers/).
- This is the official system of record for documenting to CDC defective supplies involved with a vaccine administration error or adverse event.

Retail Pharmacy Update

As early as February 11th, 2021

- The Federal Retail Pharmacy Program relies on a close collaboration between pharmacy partners, CDC, and state, local, and territorial public health departments.
- Soft roll out
 - This phase of the program is designed to engage the system in a limited way to ensure the infrastructure is ready for large scale implementation when vaccine supply increases.
- 1 million doses a week
- 21 national pharmacy chains and independent pharmacy networks
- Maine Selection: Walmart Pharmacy
- State-selected eligibility criteria

VAERS

- The federal government takes all reports of vaccine adverse events seriously, and CDC and the U.S. Food and Drug Administration (FDA) are actively engaged in safety monitoring of COVID-19 vaccines. CDC uses numerous vaccine safety monitoring systems, including VAERS, to watch for adverse events (possible side effects) after vaccination.
- Who can report post-vaccination adverse events to VAERS?
 - Anyone can submit a report to VAERS. Healthcare professionals, health departments, vaccine manufacturers, vaccine recipients, and parents or family members of people who have received a vaccine are encouraged to submit a VAERS form if they experience any adverse events after getting any vaccine.
- What do CDC and FDA do when a VAERS report is submitted?
 - Experts from CDC and FDA monitor VAERS reports to identify adverse events that need to be studied further. All serious reports are reviewed daily by vaccine safety experts. Scientists at CDC and FDA use statistical models to help understand whether there are any safety signals for a vaccine product and compare them with safety signals for other vaccines to determine if further investigation is needed.

VAERS

- When does CDC follow up on reports submitted to VAERS?
 - VAERS staff obtains follow-up medical records for reports classified as serious. A serious report describes an event that resulted in permanent disability, hospitalization, life-threatening illness, or death. VAERS staff may also obtain follow-up medical records for adverse events of interest, like anaphylaxis. Reviewing these records can help CDC and FDA medical staff better understand cases.
- Will CDC follow up with people who submit VAERS reports?
 - The person who submits a VAERS report will receive a confirmation that VAERS has received the report or a reminder if important information was left out of the initial report. If additional information is needed, CDC may reach to healthcare providers relevant to the case.
- What happens when a death is reported to VAERS?
 - When a death is reported to VAERS, CDC obtains medical records about the person's death, including an autopsy report, if available. If no autopsy was performed, CDC will obtain a death certificate and other relevant medical records. VAERS scientists will **not** reach out to the person who submitted the report, unless the name of the hospital or vaccination provider is **not** included.

COVID Vaccination Dashboard

- <https://www.maine.gov/covid19/vaccines/dashboard>

Contact Information

C19Vaccine.MECDC@maine.gov

For questions regarding vaccine planning for COVID-19:

- Vaccine planning logistics – enrolled providers only
- Any follow-up questions to these weekly Vaccine Planning Work Group Meetings

C19PA.MECDC@maine.gov

To submit documents for COVID-19 vaccine enrollment:

- CDC COVID-19 Vaccination Program Provider Agreement
- Storage & handling documentation if required

Website Information

[ImmunizeME.org](https://www.immunizeME.org)



Pediatric (0-10 years)



Adolescent (11-18 years)



Adults (19 & Older)



Pregnancy



Vaccine Clinics



For Providers



COVID-19 Providers



Questions?

Tonya Philbrick
Director
Maine Immunization Program

